AbbVie's Long-Acting Amylin Analog ABBV-295 Advances to Phase 2 in Obesity
ABBV sits 39% above its 52-week low of $190.75.
Summary
AbbVie's partner Gubra announced that ABBV-295, a long-acting amylin analog for obesity, has entered Phase 2, triggering a $50 million milestone payment to Gubra. The trial will enroll 360 adults with obesity or overweight and a comorbidity, with the primary endpoint of weight change at week 32. Phase 1 data showed up to 9.8% weight reduction with weekly dosing, supporting differentiation from GLP-1 therapies. This is a meaningful pipeline advancement for AbbVie's metabolic portfolio, though the milestone payment is immaterial to AbbVie's financials. The program's progress is a positive signal for AbbVie's obesity strategy, but the ultimate commercial impact remains years away.
At the time of this announcement, ABBV was trading at $265.32 on NYSE in the Life Sciences sector, with a market capitalization of approximately $469.7B. The 52-week trading range was $190.75 to $267.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: MFN by Modular Finance.